Synairgen plc is the holding company for Synairgen Research Limited, a drug discovery and development company focused on developing therapies which address the causes, rather than the symptoms, of respiratory disease. As at June 30, 2008, the Company’s programmes were IFN-beta, protein, collaboration and other research programmes. IFN-beta is for the treatment or prevention of exacerbations (attacks) of asthma and chronic obstructive pulmonary disease (COPD) caused by the common cold.
22/05/12
Professor Stephen Holgate given prestigious Award01/05/12
Holding(s) in Company19/04/12
Positive Phase II asthma data02/03/12
Notice of Report and Accounts01/02/12
Preliminary results30/01/12
Notice of Results12/12/11
Directors dealing08/12/11
End of Recruitment in Phase II Asthma Trial25/11/11
Positive Viral Pneumonia Study Results10/11/11
Result of AGM25/11/11
Synairgen shares up on positive results for IFN-beta in viral pneumonia study09/11/09
Synairgen shares rocket on news of positive experiment data for inhaled interferon beta04/09/09
Synairgen gears up for next stage of IFN-beta programme01/04/09
Synairgen reports encouraging data from inhaled interferon beta trial
Copyright © Proactiveinvestors.co.uk, 2012. All Rights Reserved Design & Development: Tehnicom Computers
